Chinese switch hurts Bayer
This article was originally published in OTC Bulletin & The Rose Sheet
An “unexpected” move by the China Food and Drug Administration (CFDA) to reverse-switch two of its leading OTC products, in combination with “persistently weak business development in the US”, caused Bayer’s Consumer Health sales to fall by 2.9% to €5.86 billion in 2017, the German company reported.
You may also be interested in...
Notwithstanding a particularly difficult 2018, Bayer Consumer Health still has "one of the best brand portfolios," and can continue to compete with the market leaders, says CEO Werner Baumann. Consumer Health struggled particularly in the US and Europe in the 12 months, with the majority of its leading brands recording poor performances.
Bayer's Consumer Health chief Heiko Schipper hopes a focus on innovation and a leaner portfolio will help return business to mid-single-digit growth by 2022. German firm has identified North American business as the "key area to fix."
Bayer's Consumer Health chief Heiko Schipper is hoping a focus on innovation and a leaner portfolio will help return the business to mid-single-digit growth by 2022. The German firm has identified its North American business as the 'key area to fix'.